Skip to content
OpenCapital
Get started

Perspective Therapeutics CATX Increase (Decrease) in Accrued Interest Receivable, Net

Other financials

Income statement

See full
Revenue$2.2M+27.3%
Gross profit$738.0K+78.3%
Operating income-$28.3M-29.5%
Net income-$26.2M-44.1%
EPS (diluted)-$0.250.0%

Balance sheet

See full
Cash & equivalents$54.0M+21.5%
Total debt$4.2M+10.9%
Total equity$347.4M+22.1%
Total assets$410.8M+24.7%

Cash flow

See full
Operating cash flow-$31.5M-45.8%
CapEx$6.9M+47.3%
Free cash flow-$38.3M-46.1%

Valuation

See full
Market cap$342.14M+33.2%
Enterprise value$292.34M+35.2%
P/S34.2×+19.6×

Profitability

See full
Gross margin33.1%-7.1pp
Operating margin-292.7%-553pp
Net margin-218.4%-781pp
FCF margin-1,073.3%—

Returns & leverage

See full
Return on equity-35.2%+2.3pp
Debt / equity0×0.0×
Current ratio8.7×-8.3×

Where this comes from

Reported directly by Perspective Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet.

The official record: Perspective Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Perspective Therapeutics's increase (decrease) in accrued interest receivable, net.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Perspective Therapeutics's increase (decrease) in accrued interest receivable, net?
Perspective Therapeutics (CATX) reported increase (decrease) in accrued interest receivable, net of $392K in Q1 2026.
How has Perspective Therapeutics's increase (decrease) in accrued interest receivable, net changed year-over-year?
Perspective Therapeutics's increase (decrease) in accrued interest receivable, net increased by 429.7% year-over-year, from $74K to $392K.